Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism
Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…Characteristics of prescribers for Parkinson’s disease patients: A nationwide study on 2017 Medicare data
Objective: To assess characteristics of Medicare prescribers for Parkinson’s disease (PD) patients, as a target population for delivering advanced PD care education. Background: PD is…Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…The utility of single dose levodopa challenges in the management of Parkinson’s disease
Objective: To retrospectively review the clinical utility of single dose levodopa challenges in the management of Parkinson in a tertiary movement disorder clinic. Background: Acute…Motor Fluctuations in a Real-World Sample of Patients with Parkinson’s Disease
Objective: To characterize OFF and ON times in a real-world sample of patients with Parkinson’s disease (PD) experiencing motor fluctuations (MF) with carbidopa/levodopa (CD/LD) and…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Home validation of a smartphone-based tapping task to assess medication responsiveness in Parkinson’s disease
Objective: To validate a timed tapping task (TTT) on a smartphone to ascertain differences in OFF- and ON-phases in Parkinson’s disease (PD) in the home…Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 57
- Next Page »